Article | July 15, 2021

Introduction To CAR T-Cell Therapy Part 2: Additional Considerations & Future Opportunities

By Ashley Herrick

iStock-1293772874-lab-plasmid-gene therapy-DNA

Beginning in 2017 with the approvals of tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), chimeric antigen receptor (CAR) T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies. Since those initial approvals, three other CAR T-cell therapies have been approved for various hematologic malignancies, but many challenges still limit the therapeutic efficacy of current CAR T-cell therapies and their use in solid tumors.

In our previous post, we covered the background and current development landscape for CAR T-cell therapies. In this post, we address the advantage and challenges of this approach, strategies for managing cytokine release syndrome (CRS), and the future of CAR T-cell therapy.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: